Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.31 |
| ▸ | GALR2 | O43603 | 1/20 | 0.31 |
| ▸ | GALR1 | P47211 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ITK | Q08881 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18094380 | 0.87 | ROCK1 (0.38) | P2RX3SCN9AMAP3K5TRPA1GALR2 | |
| SCHEMBL16747901 | 0.86 | P2RX3 (0.32) | P2RX3TRPA1 | |
| SCHEMBL18094395 | 0.83 | SCN9A (0.34) | FLT3HSD17B14PDE4BSCN9AGALR2 | |
| SCHEMBL18094404 | 0.83 | IDO1 (0.38) | FLT3HSD17B14P2RX3MAP3K5TRPA1 | |
| SCHEMBL18094398 | 0.76 | PDE4B (0.36) | FLT3HSD17B14PDE4BP2RX3SCN9A | |
| SCHEMBL16740266 | 0.75 | BRAF (0.36) | PDE4BP2RX3SCN9AABCB1ABCC1 | |
| SCHEMBL16747910 | 0.75 | GALR2 (0.35) | SCN9ATRPA1GALR2GALR1 | |
| SCHEMBL16747893 | 0.74 | AGPAT2 (0.36) | P2RX3GALR2GALR1ABCB1ABCC1 | |
| SCHEMBL18094409 | 0.74 | PDE4B (0.36) | FLT3HSD17B14PDE4BP2RX3SCN9A | |
| SCHEMBL16740076 | 0.73 | ABCG2 (0.34) | P2RX3SCN9ATRPA1GALR2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | FLT3 1643/4885HSD17B14 3671/4885PDE4B 3693/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | FLT3 1643/4885HSD17B14 3671/4885PDE4B 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.